One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...

Immune-related AEs and infusion reactions occurred in 42% of pembrolizumab-treated patients; these were grade 3 to 5 in 10% ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program ...

Merck’s Keytruda plus Padcev receives European approval for first-line treatment of unresectable or metastatic urothelial carcinoma in adults: Rahway, New Jersey Wednesday, Sept ...

Funds from the French Government will support clinical development for T cell-activating monoclonal antibody and another ...

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq ...